U.S. Biotech Stock News

The latest move for Nuvation Bio (NUVB) centers on Europe, where the European Medicines Agency has validated the Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer. See our latest analysis for Nuvation Bio. The EMA validation comes shortly after Nuvation Bio secured global rights to safusidenib in Japan, against a backdrop of a 7 day share price return of 8.89% but a 90 day share price return decline of 48.06%, while the 1 year total...

Centene Corporation recently announced that, effective March 18, 2026, long-time finance executive and CPA Theodore Pienkos became Corporate Controller and Chief Accounting Officer, while prior controller Kate Casso moved into a new Senior Vice President role overseeing finance operations and innovation. These leadership shifts arrive as Centene faces pressure from elevated Medicaid and ACA marketplace medical costs and the company’s decision to withdraw its 2025 guidance, placing extra...

In its recently reported second quarter of fiscal 2026, AutoZone posted earnings of US$27.63 per share with net sales up 8.2% year over year, while adding 64 new stores across the U.S., Mexico, and Brazil to reach 7,774 locations worldwide. Alongside these results, the company saw gross profit improve but operating profit ease by 1.2% and inventory grow 13.1%, reflecting the cost and complexity of its expansion and inflationary pressures. With this expansion-driven inventory build and...

Why Gartner’s recognition matters for Manhattan Associates (MANH) Manhattan Associates (MANH) was again named a Leader in Gartner's Magic Quadrant for Transportation Management Systems, its eighth consecutive appearance, after launching AI Agents within its cloud-native Manhattan Active solutions for real-time supply chain operations. See our latest analysis for Manhattan Associates. Despite the Gartner recognition and AI product launches, the 30 day share price return of 11.73% and year to...

CSG Systems International (NasdaqGS:CSGS) has entered a significant partnership with ePLDT Group to support digital solutions and enterprise services in the Philippines. The collaboration extends CSG’s platform solutions into a new Southeast Asian market within the region’s information and communications technology sector. The agreement focuses on helping enterprise clients streamline and manage their digital offerings across a growing set of services. CSG Systems International, known for...

Why earnings revisions matter for McKesson (MCK) right now Recent upward revisions to McKesson (MCK) earnings estimates, together with its record of surpassing consensus EPS in recent quarters, have put fresh attention on how the company’s pharmaceutical distribution revenue story is shaping up. See our latest analysis for McKesson. McKesson’s share price has moved to US$884.28, with a 1-day share price return of 1.37% and a 90-day share price return of 6.99%. Its 1-year total shareholder...

Diodes (DIOD) has expanded its PowerDI8080-5 N-channel MOSFET line, targeting automotive and industrial uses where efficiency, compact footprints, and reliability in electric and hybrid vehicles are central design priorities for engineers. See our latest analysis for Diodes. That product launch lands against a share price that has moved to $68.58, with a 30-day share price return of 10.81% and a 1-year total shareholder return of 86.97%. However, 3 and 5-year total shareholder returns remain...

In Q4 2025, Halozyme Therapeutics reported EPS of US$0.24 and revenue of US$451.77 million, exceeding revenue expectations but falling short on earnings, while reiterating its 2026 revenue guidance, updating 2025 guidance, and appointing David Ramsay as interim CFO on March 23, 2026. Despite the mixed quarter, analysts highlighted Halozyme’s growing royalty revenues and expanding ENHANZE partnerships as key drivers behind their more optimistic outlooks. With stronger revenue performance and...

In recent months, Tenet Healthcare reported quarterly revenue of US$5.53 billion and earnings per share of US$4.70, both ahead of consensus estimates, while analysts have become more positive on its earnings outlook. An orderly transition in Tenet’s senior finance leadership, paired with consistent earnings outperformance, highlights how its financial reporting function underpins investor confidence. We’ll now examine how Tenet’s continued earnings outperformance shapes its investment...

L3Harris Technologies recently supported the historic Artemis II crewed mission to the moon by supplying more than 100 propulsion, thruster, avionics and communications elements, including RS-25 and RL10 engines, in-space course-correction thrusters, 40 advanced avionics systems and the Orion audio system. This extensive role in a high-profile lunar mission, alongside its work on infrared tracking satellites and resilient multi-orbit communications, highlights L3Harris’s deep integration in...

What EPR Properties’ recent returns say about investor sentiment EPR Properties (EPR) has drawn fresh attention after a mixed run in its recent returns, with the share price showing a 1.7% move over the past day and a 3.8% gain over the past week. Over the past month, the stock shows an 11% decline, while the past 3 months are roughly flat. Against that backdrop, investors are weighing EPR’s US$713.961 million in revenue and US$250.792 million in net income alongside its current value score...

In late March 2026, Cimpress plc announced a new share repurchase program authorizing the company to buy back up to US$200,000,000 of its shares following the expiry of a prior plan on March 25, 2026. This fresh authorization highlights Cimpress’ willingness to return capital to shareholders, potentially altering how investors assess its capital allocation and balance-sheet priorities. We’ll now examine how this new US$200,000,000 share repurchase authorization might reshape Cimpress’...

Structure Therapeutics recently reported encouraging Phase 2 trial results for its oral obesity drug candidate aleniglipron, coinciding with renewed attention on GLP-1 weight-loss treatments following US FDA approval of a competing therapy from Eli Lilly. The combination of promising oral obesity data and rising institutional interest highlights how Structure Therapeutics has become more central to the fast-evolving obesity treatment landscape. We’ll now examine how the promising Phase 2...

On 28 March 2026, the European Space Agency announced that Rocket Lab’s Electron rocket successfully launched the “Daughter Of The Stars” mission from New Zealand, placing ESA’s first two “Celeste” low Earth orbit navigation demonstration satellites into a 510 km orbit. This mission, which maintained Rocket Lab’s 100% success record for national space programs and marked its 6th launch of 2026 and 85th overall, underscores the company’s growing role as a reliable commercial provider for...

If you are wondering whether DHT Holdings at US$18.66 still offers value after a strong run, this breakdown will help you size up the stock with a clear valuation lens. The share price performance has been strong, with returns of 4.1% over 7 days, 3.3% over 30 days, 58.9% year to date, and 96.8% over the past year. These kinds of moves can change how the market prices both potential and risk. Recent coverage has focused on DHT Holdings as part of wider discussions about oil and gas shipping...

Radware (RDWR) has drawn fresh attention after authorizing a share repurchase of up to US$80 million, completing the Pynt acquisition in API security testing, and doubling its global cloud DDoS mitigation capacity. See our latest analysis for Radware. Those moves sit alongside a 10.03% 1 month share price return and a 13.10% 3 month share price return to US$27.20. The 1 year total shareholder return of 37.30% signals building momentum compared with more muted longer term results. If this kind...

CrowdStrike and several partners recently expanded AI-focused collaborations and launched new Falcon platform capabilities across exposure management, data security, cloud risk, and agentic SOC operations, aiming to give enterprises continuous, cross-domain protection from endpoint to cloud and AI workloads. Together, these moves push CrowdStrike beyond endpoint protection toward a broader AI security and services ecosystem, where partners like IBM, Intel, AWS, and HCLTech can embed its...

H.B. Fuller (FUL) drew fresh investor attention after reporting first quarter results with sales of US$770.84 million and net income of US$21.05 million, along with higher full year 2026 revenue guidance. See our latest analysis for H.B. Fuller. The raised full year 2026 revenue guidance and stronger earnings have come alongside a 1 year total shareholder return of 16.56%, while the 3 year total shareholder return is slightly negative. This suggests improving, but still cautious, momentum...

Event driven look at Bancorp Bancorp (TBBK) has drawn fresh attention after recent share price swings, with a 1 day return of 1.5% and a 7 day move of 7.2% prompting investors to reassess the stock. See our latest analysis for Bancorp. Recent momentum has been mixed, with a 7 day share price return of 7.2% and a 30 day share price return of 5.7%, set against a 1 year total shareholder return of 36.0% and 5 year total shareholder return of 151.8%. If Bancorp's swings have you reassessing your...

In recent weeks, KKR closed its approximately US$23.00 billion North America Fund XIV and was chosen by the US Army to help build and operate a large AI-focused data centre via portfolio company CyrusOne. Together, these developments underline KKR’s ability to attract large pools of capital while expanding into critical digital infrastructure that supports accelerating AI adoption. We’ll now examine how KKR’s record North America fundraise, combined with its new AI-focused data centre...

In March 2026, Arrowhead Pharmaceuticals reported two-year open-label extension data showing durable triglyceride reductions and consistent safety for investigational plozasiran in patients with severe and mixed hypertriglyceridemia, building on earlier Phase 2b results and supporting ongoing global Phase 3 programs and regulatory plans. The data underscored plozasiran’s potential to address a lack of long-term treatment options in severe lipid disorders, including rare Familial...

Chemron (CVX) has been drawing attention after recent share price moves, with the stock up about 5% over the past month and roughly 27% in the past 3 months. See our latest analysis for Chevron. That recent 4.8% 30 day share price return and 27.1% 90 day share price return sit alongside a 48.4% 1 year total shareholder return, suggesting momentum has been building over both shorter and longer horizons. If Chevron’s move has you looking beyond a single stock, this could be a good moment to see...

Domino's Pizza (DPZ) has been back in focus after a surge in trading volume, as investors position ahead of the company’s April 27 first quarter earnings and weigh its established dividend profile. See our latest analysis for Domino's Pizza. The share price has recently picked up, with a 1 day share price return of 2.6% and 7 day share price return of 5.1%, although the 30 day share price return of 9.2% and year to date share price return of 12.8% remain weak. The 3 year total shareholder...

Huron Consulting Group (HURN) is back in focus after reporting fourth quarter results that topped analyst expectations, even as its share price slipped while investors weighed a wide 2026 guidance range and uncertainty related to AI. See our latest analysis for Huron Consulting Group. At a share price of US$130.35, Huron’s recent 1 day share price return of 1.65% and 7 day gain of 6.29% come after a 30 day share price decline of 10.00% and a 90 day share price decline of 27.95%. The 5 year...